The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and the more mutations a cancer has the more likelihood that it will produce an antigen that's recognized as non-self and that's why in the early days of immunotherapy the only things that worked were I2 against metastatic melanoma and kidney cancer because kidney cancer turned out to be also one of those cancers that for reasons that are not clear produced hundreds of mutations
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.